<DOC>
	<DOCNO>NCT00403988</DOCNO>
	<brief_summary>Study Objective : To assess efficacy safety combination Oxaliplatin , Vinorelbine without Trastuzumab salvage regimen patient Metastatic Breast Cancer</brief_summary>
	<brief_title>Vinorelbine Oxaliplatin ( Vinox ) With Without Trastuzumab ( Herceptin® ) Advanced Breast Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Metastatic , histologically cytologically proven breast cancer . At least one bidimensionally measurable lesion . Previous treatment chemotherapy first line metastatic disease mandatory especially anthracyclines +/ Taxanes . Treatment adjuvant allow . World Health OrganizationECOG performance status 02 . Adequate renal function ( Creatinine &lt; = 1.4 Creatinine clearance &gt; = 30 ml/min ) Adequate hepatic function ( Liver Function Tests 3 time normal value ) Adequate bone marrow reserve require ( Neutrophils ( PMN ) &gt; = 2000/mm2 Platelets &gt; = 100,000/mm2 ) Patient receive Herceptin overexpression HER2neu . Symptomatic peripheral neuropathy ( National Cancer Institute common toxicity criterion grade one ) . Pregnant breastfeeding . History prior malignancy ( exception excise cervical carcinomainsitu nonmelanoma cell skin carcinoma ) . Receiving receive , treatment experimental drug . Had know brain leptomeningeal involvement . Had serious medical condition like congestive heart failure Ejection Fraction ≥ 40 % . The presence bone sole site metastasis . Radiation therapy area measurable disease less four week treatment . Creatinine two time normal range Hypercalcemia Evaluable measurable disease sole site metastasis : pleural effusion Ascites Pericardial effusion . Concomitant steroid intake &gt; 4 week Bilirubin two time normal range The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>